Viking Therapeutics, Inc. (NASDAQ:VKTX)‘s stock had its “buy” rating restated by analysts at Maxim Group in a report released on Wednesday, October 4th. They currently have a $5.00 price objective on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 119.30% from the company’s previous close.
A number of other research analysts have also weighed in on VKTX. ValuEngine upgraded shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target (up from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th.
Viking Therapeutics (NASDAQ VKTX) opened at 2.28 on Wednesday. The firm’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.66. The firm’s market cap is $63.15 million. Viking Therapeutics has a 12 month low of $0.88 and a 12 month high of $2.44.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Equities research analysts predict that Viking Therapeutics will post ($0.83) earnings per share for the current year.
A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its position in Viking Therapeutics by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 102,600 shares during the period. Virtu KCG Holdings LLC purchased a new position in shares of Viking Therapeutics in the second quarter valued at about $124,000. Finally, Sabby Management LLC purchased a new position in shares of Viking Therapeutics in the second quarter valued at about $525,000. Institutional investors own 5.53% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.